Vimarsana
Biggest News Aggregation in the World

Page 11 - Spherix Network News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Spherix Network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Spherix Network Today - Breaking & Trending Today

BMS' Zeposia and AbbVie's Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn's Disease Markets, Spherix Reports - Vimarsana News

BMS' Zeposia and AbbVie's Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn's Disease Markets, Spherix Reports

/PRNewswire/ -- US gastroenterologists estimate that just under 60% of their ulcerative colitis (UC) and 55% of their Crohn's disease (CD) patients treated...

As SGLT2 Inhibitors Create Increased Market Complexities for Chronic Kidney Disease Non-Dialysis Patients, How Quickly Will Patient Care Evolve - Vimarsana News

As SGLT2 Inhibitors Create Increased Market Complexities for Chronic Kidney Disease Non-Dialysis Patients, How Quickly Will Patient Care Evolve

Share this article Share this article EXTON, Pa., March 4, 2021 /PRNewswire/ -- Chronic kidney disease (CKD) patients experience a wide range of comorbidities and risks associated with their disease, such as diabetic complications, hyperkalemia, and metabolic acidosis. At the American Society of Nephrology (ASN) fall 2020 conference, Kidney Week Reimagined, news about SGLT2 inhibitors for CKD patients with and without diabetes created a stir and caused optimism about potential paradigm shifts for CKD patients. The fierce competition between AstraZeneca and Vifor/Relypsa in the hyperkalemia...